Molecular pharmacology of CXCR4 inhibition

Novel Developments in Stem Cell Mobilization: Focus on CXCR4

Volumn , Issue , 2012, Pages 23-35

  Steen, Anne ^a   Rosenkilde, Mette Marie ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

AMD3100; G CSF; Mobilization; Progenitor cells; Stem cells

Indexed keywords

EID: 84955374995     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1960-0_2     Document Type: Chapter

References (40)

1. Klabunde T, Hessler G (2002) Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 3(10):928-944. doi:10.1002/1439-7633(20021004)3:10928:AID-CBIC9283.0.CO;2-5.
2. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE (2006) Molecular mechanism of 7TM receptor activation—a global toggle switch model. Annu Rev Pharmacol Toxicol 46:481-519. doi: 10.1146/annurev.pharmtox.46.120604.141218.
3. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW (2009) Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30(5):249-259. doi:S0165-6147(09)00054-610.1016/j.tips.2009.02.006.
4. Benned-Jensen T, Rosenkilde MM (2009) The role of transmembrane segment II in 7TM receptor activation. Curr Mol Pharmacol 2(2):140-148.
5. Schwartz TW, Rosenkilde MM (1996) Is there a “lock” for all agonist “keys” in 7TM receptors? Trends Pharmacol Sci 17(6):213-216. doi:0165614796100171.
6. Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3(9):639-650. doi:10.1038/nrm908 nrm908.
7. Hubbell WL, Altenbach C, Hubbell CM, Khorana HG (2003) Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv Protein Chem 63:243-290.
8. Altenbach C, Kusnetzow AK, Ernst OP, Hofmann KP, Hubbell WL (2008) High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proc Natl Acad Sci USA 105(21):7439-7444. doi:080251510510.1073/pnas.0802515105.
9. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455(7212):497-502. doi:nature07330 10.1038/nature07330.
10. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP (2008) Crystal structure of the ligandfree G-protein-coupled receptor opsin. Nature 454(7201):183-187. doi:nature07063 10.1038/nature07063.
11. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK (2011) Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469(7329):175-180. doi:nature0964810.1038/nature09648.
12. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M, Gmeiner P, Kobilka BK (2011) Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 469(7329):236-240. doi:nature0966510.1038/nature09665.
13. Yao XJ, Velez Ruiz G, Whorton MR, Rasmussen SG, DeVree BT, Deupi X, Sunahara RK, Kobilka B (2009) The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci USA 106(23):9501-9506. doi:081143710610.1073/pnas.0811437106.
14. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318(5854):1266-1273. doi: 115060910.1126/science. 1150609.
15. Steen A, Schwartz TW, Rosenkilde MM (2009) Targeting CXCR4 in HIV cell-entry inhibition. Mini Rev Med Chem 9:1605-1621. doi:MRMC Epub-055.
16. Izatt RM, Pawlak K, Bradshaw JS, Bruening RL (1991) Thermodynamic and kinetic data for macrocycle interactions with cations and anions. Chem Rev 91(8):1721-2085. doi:10.1021/cr00008a003.
17. Adam KR, Antolovich M, Atkinson IM, Leong AJ, Lindoy LF, McCool BJ, Davis RL, Kennard CHL, Tasker PA (1994) On the nature of the host-guest interaction between cyclam and 4-tert- butylbenzoic acid-a system pre-assembled for metal complex formation. J Chem Soc Chem Commun 13:1539-1540.
18. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, Alizon M (1998) Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72(8):6381-6388.
19. Schwartz TW (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5(4):434-444.
20. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12(4):1693-1703.
21. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW (2001) Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276(17): 14153-14160. doi:10.1074/jbc.M010429200 M010429200.
22. Troutner DE, Simon J, Ketring AR, Volkert W, Holmes RA (1980) Complexing of Tc-99m with cyclam: concise communication. J Nucl Med 21(5):443-448.
23. Este JA, Cabrera C, De Clercq E, Struyf S, Van Damme J, Bridger G, Skerlj RT, Abrams MJ, Henson G, Gutierrez A, Clotet B, Schols D (1999) Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol Pharmacol 55(1):67-73.
24. Gerlach LO, Jakobsen JS, Jensen KP, Rosenkilde MR, Skerlj RT, Ryde U, Bridger GJ, Schwartz TW (2003) Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. Biochemistry 42(3):710-717. doi:10.1021/bi0264770.
25. Rosenkilde MM, Gerlach LO, Jakobsen JS, Skerlj RT, Bridger GJ, Schwartz TW (2004) Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 279(4):3033-3041. doi:10.1074/jbc.M309546200 M309546200.
26. Hatse S, Princen K, Bridger G, De Clercq E, Schols D (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527(1-3):255-262. doi: S0014579302031435.
27. Bridger GJ, Skerlj RT, Padmanabhan S, Martellucci SA, Henson GW, Abrams MJ, Joao HC, Witvrouw M, De Vreese K, Pauwels R, De Clercq E (1996) Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicy- clams. J Med Chem 39(1):109-119. doi:10.1021/jm950584t jm950584t.
28. Joao HC, De Vreese K, Pauwels R, De Clercq E, Henson GW, Bridger GJ (1995) Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J Med Chem 38(19):3865-3873.
29. Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ, Schwartz TW (2007) Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 282(37):27354-27365. doi:M70473920010.1074/jbc.M704739200.
30. Wong RS, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP (2008) Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74(6):1485-1495. doi:mol.108.04977510.1124/mol. 108.049775.
31. Moyle G, DeJesus E, Boffito M, Wong RS, Gibney C, Badel K, MacFarland R, Calandra G, Bridger G, Becker S (2009) Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 48(6):798-805. doi:10.1086/597097 10.1086/597097.
32. Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, Minoguchi S, Tamamura H, Waki M, Matsumoto A, Fujii N, Shida H, Hoxie JA, Peiper SC, Yamamoto N (1999) Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 73(9):7489-7496.
33. Tamamura H, Imai M, Ishihara T, Masuda M, Funakoshi H, Oyake H, Murakami T, Arakaki R, Nakashima H, Otaka A, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N (1998) Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12), Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg Med Chem 6(7):1033-1041. doi:S0968-0896(98)00061-3.
34. Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N et al (1994) Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun 205(3):1729-1735. doi:S0006291X84728683.
35. Abraham M, Beider K, Wald H, Weiss ID, Zipori D, Galun E, Nagler A, Eizenberg O, Peled A (2009) The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 23(8):1378-1388. doi:leu20095610.1038/leu.2009.56.
36. Trent JO, Wang ZX, Murray JL, Shao W, Tamamura H, Fujii N, Peiper SC (2003) Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 278(47):47136-47144. doi:10.1074/jbc.M307850200 M307850200.
37. Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, Nakashima H, Otaka A, Fujii N (2000) Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett 10(23):2633-2637. doi:S0960-894X(00)00535-7.
38. Vabeno J, Nikiforovich GV, Marshall GR (2006) A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists. Biopolymers 84(5):459-471. doi:10.1002/bip. 20508.
39. Vabeno J, Nikiforovich GV, Marshall GR (2006) Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor. Chem Biol Drug Des 67(5):346-354. doi:JPP38710.1111/j. 1747-0285.2006.00387.x.
40. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330(6007): 1066-1071. doi:science. 1194396s10.1126/science.1194396.